When several heart medications were found to be contaminated with varying levels of two compounds that are suspected of being human carcinogens, most reports confidently named valsartan as the culprit. Several lots of medications containing valsartan manufactured primarily in Chinese laboratories were found to contain trace amounts of compounds known as NDMA and NDEA. Subsequent testing lead to recalls being issued in both the United States and Canada while ...
continue reading...Contamination Leads to Cancer Risk in Another Heart Medication
Posted November 15, 2018 in Drug and Medical Device Lawsuits | Product News and Recalls